Shares of OncoGenex went into meltdown mode this morning after the biotech and its partner Teva put out word that their experimental prostate cancer drug had flunked a long-awaited Phase III study. Shares of OncoGenex immediately shed more than half their value in the reckoning with investors.
Biogen Idec has struck up a far-reaching agreement with CRO giant Quintiles, tapping the contractor to help design, plan and run its Phase II-IV studies.
Cytokinetics has some thinking to do after its lead program missed the mark in a Phase IIb trial, failing to move the efficacy needle in ALS, commonly known as Lou Gehrig's disease.
Amgen is getting aggressive with one of its midstage leukemia drugs. In its earnings call with analysts the big biotech's R&D chief called out blinatumomab, saying that recent Phase II data might warrant an early approval.
A few weeks after Seattle-based Alder Biopharmaceuticals spelled out plans to raise $115 million in an IPO designed to propel them into the ranks of a fully diversified biotech company, the biotech has released some key data points from its proof-of-concept study on its experimental migraine therapy.
After keeping investors on a roller coaster ride of speculation for months, Sarepta says it now plans to shoot for an accelerated approval of its Duchenne muscular dystrophy drug eteplirsen. The biotech says it will file for an early approval by the end of this year after launching a slate of new clinical trials to get the data that the FDA is looking for.
Zafgen has been turning heads with some jaw-dropping results from its mid-stage studies for a promising new obesity drug. And now the biotech hopes to parlay its eye-catching, if risky, technology into an $86 million IPO.
FDA and EMA requests for more data on hepatitis B candidate Heplisav have set Dynavax Technologies back time and again. Now, Dynavax is embarking on a new trial it hopes will address some of those safety concerns.
The newly downsized Texas-based Lexicon Pharmaceuticals says it nailed promising data on its experimental diabetes drug, positioning it for a late-stage study that could leave it poised to compete with a full lineup of rival treatments already brought to the market by a group of pharma giants.
A few months ago Roche put out the word that its schizophrenia drug bitopertin had flunked the first two Phase III studies in a lengthy lineup of clinical trials. And today the pharma giant almost completed its obituary for a drug program that had been touted as one of Roche's top blockbuster prospects, adding a long slate of trial flops to the record.